相关临床试验
74
34 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
31
41.9%
已完成
21
28.4%
尚未招募
3
4.0%
招募中
6
8.1%
终止
5
6.8%
Unknown
8
10.8%
暂无批准数据
- Artelo Biosciences has secured a fully funded investigator-sponsored clinical trial to evaluate ART27.13, its peripherally selective synthetic cannabinoid, in glaucoma patients with first enrollment expected in Q2 2026. - The study is funded by Glaucoma UK and HSC R&D Division, targeting the $16.3 billion global glaucoma market projected to grow at 7.05% annually through 2033. - ART27.13's peripheral selectivity may overcome historical limitations of cannabinoid therapies by avoiding central nervous system side effects while potentially reducing intraocular pressure through novel mechanisms. - This capital-efficient development strategy expands ART27.13's therapeutic potential beyond its lead indication in cancer-related anorexia without requiring additional shareholder investment.
- Panakeia's PANProfiler Colorectal (MSI/MMR) software demonstrated 93.83% agreement with standard laboratory testing in the largest real-world, multi-site validation study of AI molecular profiling to date. - The AI software successfully returned results on 86.55% of cases across 1,243 colorectal cancer patients from three UK healthcare institutions, delivering molecular biomarker analysis in minutes rather than weeks. - Published in npj Digital Medicine, the study addresses critical gaps in molecular testing access, with national audits showing substantial proportions of eligible patients experience testing delays of several weeks. - The UKCA-marked software is now deployed in UK hospitals and selected for the MHRA's AI Airlock programme, positioning it for broader healthcare system implementation.
